Concord Biotech has achieved a significant milestone with the successful completion of an inspection by the Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food and Drug Administration (KFDA). The inspection took place at Manufacturing Unit I, an API facility in Dholka, Gujarat, from February 18 to February 20, 2025.
This accomplishment highlights an unwavering commitment to maintaining world-class quality systems and regulatory compliance. Adhering to international standards ensures the consistent delivery of high-quality pharmaceutical products, strengthening its position as a trusted industry leader.
In the meantime, Concord Biotech shares opened at ₹1,655.00, reaching a high of ₹1,710.05 and a low of ₹1,622.00. The stock’s 52-week high stands at ₹2,664.00, while the 52-week low is ₹1,327.05.
